Pharmaceuticals, Biotechnology and Life Sciences
Swedish Orphan Biovitrum (Sobi) has received approval from the European Medicines Agency (EMA) for the grouped type II 15 K Variation for Elocta (efmoroctocog alfa), recombinant extended half-life factor VIII Fc fusion protein product for the treatment of haemophilia A.
Arix Bioscience and Takeda will work together to combine complementary skills and experience across important therapeutic areas in a strategic deal.
Biocartis Group has posted net income loss of €50.2 million for 2016, which is loss increase compared to last years €39.7 million net loss.
Eli Lilly’s senior vice president of global quality Fionnuala Walshis retiring after almost three decades at the company. Her replacement will be
PureTech Health has named Bharatt Chowrira as its President and Chief of Business and Strategyto work with the Chief Executive on strategy, corporate and business development, and value realisation across PureTech Health’s pipeline, the company said in its annoucement on Thursday.
Board of Directors has appointed its former executive vice preisdent Claus Bo Svendsen, as Chief Executive Officer, as it plans to pursue important objectives related to the the Settlement and License Agreement with Biogen.
Eli Lilly has completed acquisition of CoLucid Pharmaceuticals at a price of $46.50 per share through a second-step merger.
The U.S. Food and Drug Administration (FDA) approved Lexicon Pharmaceuticals’ Xermelo tablets in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea that SSA therapy alone couldn’t control properly.
Stellar Biotechnologies and biopharmaceuticals manufacturer Amaran Biotechnology have entered into an exclusive multi-year supply agreement regarding studies of immunotherapies for various cancers, including breast cancer.
Novartis is making progress in its bid to catch rivals developing drugs that harness the immune system to fight cancer, one of its top research scientists and latest recruit from Harvard University told Reuters in an interview